Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Bio Path stock

Learn how to easily invest in Bio Path stock.

Bio Path Holdings Inc is a biotechnology business based in the US. Bio Path shares (BPTH) are listed on the NASDAQ and all prices are listed in US Dollars. Bio Path employs 10 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Bio Path

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BPTH – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Bio Path stock price (NASDAQ: BPTH)

Use our graph to track the performance of BPTH stocks over time.

Bio Path shares at a glance

Information last updated 2022-10-03.
Latest market close$3.36
52-week range$2.68 - $5.40
50-day moving average $3.71
200-day moving average $3.64
Wall St. target price$11.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.60

Buy Bio Path shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$0
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Public
Stocks, ETFs, Cryptocurrency
$0
$0
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Bio Path stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Bio Path price performance over time

Historical closes compared with the close of $3.36 from 2022-10-04

1 week (2022-09-29) 4.93%
1 month (2022-09-06) -6.67%
3 months (2022-07-06) -20.00%
6 months (2022-04-06) -11.35%
1 year (2021-10-02) N/A
2 years (2020-10-06) -21.68%
3 years (2019-10-04) 9.22
5 years (2017-10-05) 793.62%

Bio Path financials

Gross profit TTM $0
Return on assets TTM -30.1%
Return on equity TTM -50.95%
Profit margin 0%
Book value $2.73
Market capitalisation $22.8 million

TTM: trailing 12 months

Bio Path share dividends

We're not expecting Bio Path to pay a dividend over the next 12 months.

Have Bio Path's shares ever split?

Bio Path's shares were split on a 1:20 basis on 18 January 2019. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Bio Path shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Bio Path shares which in turn could have impacted Bio Path's share price.

Bio Path share price volatility

Over the last 12 months, Bio Path's shares have ranged in value from as little as $2.68 up to $5.4. A popular way to gauge a stock's volatility is its "beta".

BPTH.US volatility(beta: 1.45)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bio Path's is 1.4483. This would suggest that Bio Path's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Bio Path overview

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Frequently asked questions

What percentage of Bio Path is owned by insiders or institutions?
Currently 0.475% of Bio Path shares are held by insiders and 5.757% by institutions.
How many people work for Bio Path?
Latest data suggests 10 work at Bio Path.
When does the fiscal year end for Bio Path?
Bio Path's fiscal year ends in December.
Where is Bio Path based?
Bio Path's address is: 4710 Bellaire Boulevard, Bellaire, TX, United States, 77401
What is Bio Path's ISIN number?
Bio Path's international securities identification number is: US09057N3008
What is Bio Path's CUSIP number?
Bio Path's Committee on Uniform Securities Identification Procedures number is: 04744L106

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site